Clearside Biomedical 配当と自社株買い

配当金基準チェック /06

Clearside Biomedical配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-216.5%

バイバック利回り

総株主利回り	-216.5%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブの更新 • Dec 15

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

分析記事 • Jun 24

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

分析記事 • Nov 12

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

分析記事 • Aug 11

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

The analysts covering Clearside Biomedical, Inc. ( NASDAQ:CLSD ) delivered a dose of negativity to shareholders today...

Seeking Alpha • Aug 08

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.13 (-18.2% Y/Y) and the consensus Revenue Estimate is $0.3M (-61.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Seeking Alpha • Apr 13

Clearside Biomedical: A Pivotal 2022 Ahead

XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3. Partner Aura Biosciences will select the route of administration for lead drug candidate AU-011. Clearside is actively seeking gene therapy partners.

Seeking Alpha • Dec 22

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration. Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal injection drug XIPERE for treatment of patients with macular edema associated with uveitis. XIPERE is expected to launch in the 1st half of 2022, and Clearside has already received a $19 million pre-commercial milestone payment for it. Other established pharmaceutical companies exploring the use of the SCS microinjector for suprachoroidal delivery of their eye drugs are REGENXBIO and Aura Biosciences.

分析記事 • Sep 30

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Aug 07

Clearside's Value Proposition Is Far From Clear

Clearside is developing treatments for diseases of the suprachoroidal space of the eye. However, even its latest stage asset has very little monetary value. Self-owned programs are in early stages and face stiff competition.

分析記事 • Jun 17

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

決済の安定と成長

配当データの取得

安定した配当: CLSD.Qの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: CLSD.Qの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Clearside Biomedical 配当利回り対市場

CLSD.Q 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (CLSD.Q)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Pharmaceuticals)	2.1%
アナリスト予想 (CLSD.Q) (最長3年)	n/a

注目すべき配当: CLSD.Qは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: CLSD.Qは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: CLSD.Qの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: CLSD.Qが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/21 14:19
終値	2026/05/21 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Clearside Biomedical, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。8

アナリスト	機関
Esther Lannie Hong	Brean Capital Historical (Janney Montgomery)
Debanjana Chatterjee	JonesTrading Institutional Services, LLC
Anupam Rama	J.P. Morgan

Clearside Biomedical 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

First Motion for Exclusivity Period Extension Approved For Clearside Biomedical, Inc.

Clearside Biomedical Files Form 15

CLSD.Q: Bankruptcy Sale Process Will Unlock Significant Equity Upside

Clearside Biomedical, Inc. To Be Delisted from Nasdaq

Clearside Biomedical, Inc. Receives Delisting Notice from Nasdaq

Clearside Biomedical, Inc. Filed for Bankruptcy

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Clearside Biomedical, Inc. Receives A Non-Compliance Notice from the Listing Qualifications Department of Nasdaq

Clearside Biomedical Receives Staff Determination Letter from Nasdaq Due to Failure to Regain Compliance with the Minimum Bid Price Requirement within the 180-Calendar Day Grace Period

Clearside Biomedical Announces Approval of XIPERE Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical, Inc. Announces Reduction in Force

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Clearside Biomedical Data Featured in Six Presentations At Association for Research in Vision and Ophthalmology 2025 Meeting

Clearside Biomedical, Inc. to Report Q1, 2025 Results on May 14, 2025

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Clearside Biomedical, Inc., Annual General Meeting, May 30, 2025

Clearside Biomedical, Inc.'s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical’S Asia-Pacific Partner, Arctic Vision, Announces Acceptance of Its New Drug Application for Arcatus® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

Clearside Biomedical Announces Additional Data from the Cls-Ax Oysysy Phase 2B Trial Presented At the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical, Inc. Announces Its Asia-Pacific Partner, Arctic Vision, Receives Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

配当金基準チェック /06